JPRN-jRCT1041220027招募中2 期
Phase II study of FOLFIRINOX for the patients with resectable or borderline resectable pancreatic adenocarcinoma
Yamashita Tatsuya0 个研究点目标入组 50 人开始时间: 2022年6月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •Pathologically diagnosed as pancreatic adenocarcinoma or adenosquamous carcinoma; diagnosed as resectable or borderline resectable (BR-PV) (cohort1) or borderline resectable (BR-A); 20-80 years or older; ECOG Performance status 0 or 1; preservation of major organ function; written informed consent
排除标准
- •double cancer; severe infection; refractory ascites or pleural effusion; pregnant or lactating women, or women of childbearing potential; metastases to central nervous system; mental disorder; severe complication; patients who investigator regards as inappropriate for candidate
研究者
相似试验
已完成
2 期
A phase II study of FOLFIRINOX in patients with advanced biliary tract cancerBiliary tract cancerJPRN-UMIN000020801Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo35
尚未招募
2 期
Converison therapy of FOLFIRINOX in patients with unresectable locally advanced pancreatic cancer: A phase IInresectable locally advanced pancreatic cancerJPRN-UMIN000014039Yokohama City University50
已完成
不适用
Feasibility and efficacy of FOLFIRINOX therapy in patients with borderline resectable pancreatic cancer in the neoadjvant setting.Borderline resectable pancreatic cancerJPRN-UMIN000034509Department of Hepatobiliary Pancreatic Surgery, Saitama Medical Center, Saitama Medical University30
进行中（未招募）
1 期
_RAS and B-RAF wild-type metastatic colorectal cancer.MedDRA version: 19.0Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2016-001490-33-FRICANCER209
已完成
不适用
Observational study of FOLFIRINOX therapy for unresectable and recurrence pancreatic cancerunresectable and recurrence pancreatic cancerJPRN-UMIN000014658Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC)329